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Eleven consecutive patients with progressive chronic inflammatory de- 
myelinating polyradiculoneuropathy (CIDP) underwent plasma ex- 
change. Eight patients were previously unresponsive to prednisone, 
two were started on prednisone with plasma exchange, and one did not 
receive corticosteroids. Electrodiagnostic studies revealed evidence of 
an acquired demyelinating polyradiculoneuropathy with varying de- 
grees of axonal degeneration. Neurologic impairment was monitored 
using conventional functional status index. Five patients demonstrated 
substantial clinical improvement, beginning 2 days to 3 weeks after 
initiating plasma exchange. Two additional patients improved following 
a second course of plasma exchange, and four patients demonstrated 
minimal or no change. Comparison of responding and nonresponding 
patients showed no differences related to the presence or absence of 
antecedent illness, duration of disease, duration of maximum weak- 
ness, or severity of impairment prior to plasma exchange. Responders 
had significantly prolonged F-response and motor distal latencies com- 
pared to nonresponders. Results in this unselected, consecutive pa- 
tient trial suggest a temporal relationship between plasma exchange 
and clinical improvement in some patients with progressive CIDP. 
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PLASMA EXCHANGE IN CHRONIC INFLAMMATORY 
DEMYELINATING POLYRADICULONEUROPATHY 
PETER D. DONOFRIO, MD, RUP TANDAN, MD, 
and JAMES W. ALBERS, MD, PhD 
Chronic  inflammatory demyelinating polyra- 
diculoneuropathy (CIDP) is a diffuse, multifocal, 
idiopathic, peripheral nervous system disorder of 
presumed immunologic etiology. It is manifested 
as a slowly progressive or monophasic illness with 
stabilization in the majority of patients, but a re- 
lapsing and remitting course is seen in approxi- 
mately one-third of patients.' Frequently, CIDP 
follows a nonspecific infection, immunization, or 
exposure to immunogenic material.' Weakness in- 
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volves cranial, truncal, and proximal and distal 
musculature; large fiber sensor): modalities tend t o  
be more involved than those mediated by small 
fibers. 'There is pathologic evidence of rnononu- 
clear cell infiltration, segmental demyelination, 
and hypertrophic changes, which are most com- 
monly observed in spinal roots, spinal ganglia, and 
proximal nerve trunks.' Electrodiagnostic testing 
reveals many of the following findings: severe 
motor and sensory conduction velocity slowing, 
conduction block, and dispersion of motor evoked 
responses on proximal stimulation; prolonged dis- 
tal and F-response latencies; and abnormal sensory 
evoked response ampl i t~des ." .~  
Numerous treatment modalities have been 
thioprine ,4q6. I 4 q  1 H * P 6  cyclophosphamide ,"."' ni- 
trogen mustard,") poly-ICLC," and plasma ex- 
sults. Based on our initial experience with a patient 
with relapsing CIDP who demonstrated dramatic 
improvements following interval plasma exchange, 
we began a consecutive, nonrandomized trial of  
plasma exchange in patients with progressive 
CIDP. This article summarizes our results in 11 
unselected patients. 
reported, including corticosteroids" - " .20325 aza- 
1*12*'6*1 7*21.24.2.i All have led t o  variable re- 
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WA I LHIALS AND METHODS 
Diagnostic criteria for CIDP were similar- to those 
described by Dyck et al.,' including (1) absence of 
toxic exposure 01- associated disease commonly 
known to result in a neuropathy or polyradic- 
uloneuropathy; (2) frequent history of a preced- 
ing infection o r -  biologic material exposure; (3) 
steadily progressive deterioration; (4) relatively 
symmetric limb involvement; (5) predominance of' 
large fiber sensory involvement; (6) cerebrospinal 
fluid cytoalbuniin dissociation; and (7) unequivocal 
electrodiagnostic evidence of multifbcal conduc- 
tion slowing, partial or complete conduction block, 
and variable amounts of superimposed axonal in- 
volvement obtained using the techniques described 
below. None of the patients was subsequently 
discovered to have other causes of adult onset 
demyelinating polyneuropathy or polyratliculo- 
neuropathy. i.e., diabetes, osteosclerotic myeloma, 
or benign monoclonal gammopathy. All patients 
had a chronic progressive relentless neurologic ini- 
pairnient for at least 3 months (range 3-22 
months) prior to inclusion, and most were either 
corticosteroid unresponsive or intolerant. (Two 
patients received predriisorie simultaneously with 
plasma exchange.) Only one patient subsequently 
developed a clinical course more appropriately 
categorized as recurrent. 
A disease duration of 3 months was used to be 
reasonably assured that patients with acute iiiflani- 
rnatory demyelinating ~,olyradiculoneuropathy 
(AIDP) would be excluded. Most patients were re- 
ferred from other institut.ions, where high-dose 
corticosteroids had been initiated for a variable pe- 
riod of time prior 10 referral. 1)uring the study 
period, we excluded the following patients with 
other forms of' adult-onset deniyelinat.ing poly- 
radiculoneuropathy (number of patients in paren- 
theses): relapsitig (;IDP and steroid-responsive 
CIDP (16), nonmalignant monoclonal ganimop- 
athy (7), and osteosclerotic myeloma ( I ) .  
Motor and sensory conduction studies were 
performed using standard techniques of supra- 
maximal percutaneous stimulation and surface 
electrode recording. Compound muscle action po- 
tential (CMAP) and sensory nerve action potential 
(SNAP) amplitudes were measured from baseline 
to negative peak. Conduction velocity was niea- 
sured in the forearm or leg segment, and distal 
latency was converted as terminal conduction ve- 
locity. Conduction study results for individual 
nerves were expressed a percentage of' the normal 
mean for each nerve, then averaged and reported 
as a percentage of normal for motor and sensory 
studies. 
Motor temporal dispersion was estimated ;is the 
ratio of the proximal to the distal CMAP am- 
plitude. F-response latencies were recorded ;IS the 
minimal latency in a series of 10 F-responses using 
distal (wrist or ankle) antidromic motor nerve 
stimulation. Bot.h temporal dispersion and F- 
response latencies were averaged for individual 
patients. 'remporal dispersion was reported as an 
absolute percentage; F-response latency w a s  re- 
ported as a percentage of the upper liriiit of nor- 
mal. Median (motor and sensory), ulnar (motor), 
peroneal (motor), tibia1 and sural riervrs were evai -  
uated. 
Criteria fbr demyelination required demoii- 
stration of at least one of the followirig iii t w o  or  
more nerves (except ions noted) : 
1. Conduction velocity less than 95%. of lower limit 
of normal if  aniplitude exceeded 50% of lower 
limit of normal, less than 85?6 i f  aniplitiide less 
than 5070 of lower limit of' normal. Excluded 
were isolated ulnar 01- peroneal nerve abnor- 
malities at the elbow or knee, respectively. 
2. Distal latency exceeding 1 10% 01' upper liriiit of  
normal i f '  amplitude normal, execdiiig 120% o f  
upper limit of normal if amplitude less than  
lower limit of normal. Excluded 1vel-e isolated 
median nerve abnormalities at the wrist. 
3. Evidence of excessive motor nerve temporiil 
dispersion, defined as a proximal to distal 
CMAP amplitude ratio less than '70%,. Excluded 
were isolated ulnar or peroneal lesions, as 
above, as well as any studies with evidence of 
anomalous innervation (e.g., median to ulnar 
nerve crossover). 
4. F-response latency exceeding 120% of uppe1- 
limit of normal with combined exclusions from 
above. 
All needle electromyography recordings were 
performed using standard concentric needle elcc- 
trodes. Spontaccms activity (fibrillation potentials 
or positive 1:dves) were recorded in a given muscle 
as 0 = none, 1 + = persistent single trains iri at 
least two areas away from the entiplate, 2 +  = 
moderate numbers in three or more areas, 3 + = 
many in all areas, and 4 + = filling the baseline in 
all areas. Motor unit action potential (MUAP) re- 
cruitment was graded subjectively using 0 = none, 
1 + = severe decrease, 2 + = moderate decrease, 
3 + = mild decrease, and 4 + = normal. S l ~ n -  
taneous activity and MUAP recruitment was re- 
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Table 1. Clinical grading of neurologic impairment or 
improvement. 
~ 
Functional status index (FSI) 
0-Normal 8-Crutches 
1-Walk alone (minimal impairment) 
2-Walk alone (mild weakness) 10-Assistance 
3-Walk alone (moderate weakness) 
4-Walk alone (moderate impairment) 12-Wheelchair 
5-Walk alone (marked impairment) 
6-Cane 16-Respirator 
7-Wal ker 21 -Dead 




13-Confined to bed 
ported as an average for proximal and distal mus- 
cles. For all studies, skin temperatures were 
measured and maintained above 32°C using either 
warm compresses or an infrared heater. 
Plasma exchange was executed using either an 
IBM 2997 Blood Cell Separator (International 
Business Machine Biomedical Systems, Cranbury, 
NJ) or a Haemonetics Model 30 Blood Cell Separa- 
tor (Haemonetics Corp., Braintree, MA). Each 
patient received five separate exchanges of one 
plasma volume per exchange over a 10-14-day 
course. As a second course of plasma exchange, 
patient 6 received one plasma volume exchange 
per month for five consecutive months. Replace- 
ment fluid consisted of 5% normal serum albumin 
and, when necessary for hypofibrinogenemia, 2 U 
of single donor plasma. 
Neurologic impairment was numerically as- 
sessed using a conventional functional status index 
(FSI; Table 1). 
Clinical Characteristics. There were four males 
and seven females, having an average age of 50 
years (range 18-73). Major clinical manifestations 
are summarized in '[able 2. Approximately half of 
the patients described an identifiable antecedent 
event (either surgery or respiratory tract infection) 
predating their neurologic illness by days t o  weeks. 
Initial symptoms were sensory in five patients, 
motor in five, and combined sensory and motor in 
the remaining patient. Impaired gait was the initial 
motor complaint in all patients. Sensory delicits in- 
volved presumed small and large fiber modalities, 
with abnormalities of the latter predominating. 
Autonomic symptoms and signs, sensory tremor, 
and respiratory impairment were relatively infre- 
quent. Cranial nerve abnormalities included facial 
diplegia (three patients), equivocal orbicularis oculi 
weakness (eight patients), and pharyngeal weak- 
ness (one patient). 
Analyses of blood and urine were unremark- 
able; no patients were subsequently found to have 
diabetes, vasculitis, osteosclerotic myeloma, 01- ;I 
benign monoclonal gammopathy. Cerebral spinal 
fluid (CSF) protein was elevated in all patients. 
Eight patients had been treated with high-dose 
corticosteroids prior to plasma exchange and were 
cont.inued on this dosage during and for 1 month 
following plasma exchange, whereafter a tapering 
dosage schedule similar to that suggested by 
Dalakas and Engel" was initiated. No other ini- 
munosuppressants were prescribed. T w o  patients 
were started on high-dose corticosteroids (60 arid 
80 nig prednisone) within days of plasma ex- 
change; in a third patient, corticosteroid treatinem 
was judged to be contraindicated (prior gastroin- 
testinal bleeding). 
RESULTS 
Seven o f the  1 1  patients demonstrated clinical hi- 
provement following plasma exchange ('l'able 3), 
Table 2. Clinical data 
Auto- Distri Respi- Cranial Highest 
Patient Antecedent Initial insta- of involve- involve- involve- Treatment protein 
prior to PE (mg'dl) no Age Sex 
nomic bulion Sensory ratory nerve CSF 
event symptoms bility weakness rnent Tremor ment rnent _ _  
- D > P  S > L  + ~ ~ Corticosteroids' 153 
D > P  L > S  - ~ ~ Codicosteroids 99 
M D > P  L = S  - ~ ~ Corticosleroids' 126 
D > P  L > S  + ~ + Corticosteroids 180 
24 F Respiratory S D > P  L > S  - ~ Corticosteroids 70 
58 F None M + D > P  L = S  - + V  ~ Codicosteroids 55 
61 F None M - D > P  L = S  - + V  + 82 
33 M None M - D > P  L = S  - t V  + Corticosteroids 432 
64 F None S - D > P  L - - Cofiicosteroids 107 
18 F None M D > P  L = S  - ~ ~ Corticosteroids 126 
1 53 M Respiratory S 
2 
3 58 F Surgery S M  
4 73 M Surgery 






1 1  
S sensory M motor 0 drstal. P proxrmal + present - absent 1 large fiber S small fiber V venfilalor dependent PE plasma exchange 
'S,multaneous with onset of plasma exchange 
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Table 3. Clinical response to plasma exchange (PE) 
_ _ _ ~  
Change in Substantial Scores (FSI) 
following PE Onset Onset Duration Time following Patient to PE to peak plateau PE to FSI FSI at improvement 






















































6 6 6 3 1  
1 0 9 7 6 '  
9 8 6 5 5  
12 12 7 5 4 
8 
5 4 4 3 1  
8 8 8 - -  
8 -  5 5 5 
13 13, 13 21 21 
16 16 16 - 21 
13 13 16 21 - 
2 2 1 1 1  
' 2 1 0 '  
- - _ - -  
- 
+ 7  
+ 5  
+ 6  






+ 5  
- 1  
Yes (second PE) 
+ 3  
1 - 3  
0 
- 3  
+ 1  
+ 4  






'No  follow-up 
tDuring second course of PE ( I  exchangeimo for 5 mo). 
using an arbitrary definition of improvement as an 
increase of three or more points on the FSI scale 
by the third month following plasma exchange. 
Three months was chosen because of previous ex- 
perience with plasma exchange in another patient 
with the relapsing form of CIDP (not included in 
this study). In this patient, objective clinical im- 
provement was noted not only 1-2 weeks post 
plasma exchange, but also steadily for several 
months. Thus, three months represented a suffi- 
cient time frame for observation of initial, pro- 
longed, and potentially delayed improvement. 
Progressive improvement occurred in the setting 
of a steroid taper in all responding patients. Pa- 
tient 7 was not classified as a responder to plasma 
exchange, because her change in FSI scale merely 
reflected weaning from mechanical ventilation, 
without an improved forced vital capacity or im- 
proved extremity function. Initial improvement 
occurred on an average of 12 days following initia- 
tion of plasma exchange. Two patients noted sub- 
jective improvement within 2 days of treatment. 
Both patients who were simultaneously started on 
corticosteroids and plasma exchange improved; 
the degree of improvement did not differ from 
that of patients who were previously steroid unre- 
sponsive or intolerant. In addition, two other pa- 
tients who were unresponsive to an initial trial of 
plasma exchange improved after or during a sec- 
ond course of plasma exchange. No other im- 
munosuppressant medications were administered 
with plasma exchange. Response to plasma ex- 
change was not related to any of the following: 
duration of disease prior to plasma exchange, time 
from onset to maximum neurologic deficit, dura- 
tion of maximum weakness plateau, or FSI score 
prior to plasma exchange. 
Analysis, as a separate group, of the eight pa- 
tients who were previously refractory to high-close 
corticosteroids disclosed response to plasma ex- 
change in five patients. Improvement (average 3 
FSI grades) was noted 1 month subsequent to 
plasma exchange in three patients (patient 5 fol- 
lowing the second course of exchange) and in all 
five patients at 3 months (average 4.6 FSI grades) 
and 6 months (average 5.4 FSI grades). T w o  of the 
three patients not responding to plasma exchange 
died within 6 months of treatment secondary to 
severe unrelated medical problems. At 3- and 6- 
month follow-ups, patient 10 showed a 1 grade FSI 
improvement while undergoing corticosteroid ta- 
pering. 
Plasma exchange was free of serious complica- 
tion in all 11 patients. On one occasion, patient 3 
developed a transient urticaria1 reaction to single 
donor plasma adminstered for hypofibrinoge- 
nemia. 
The electrodiagnostic findings for patients re- 
sponding and those not responding to plasma ex- 
change are shown in Table 4. Taken together, 
none of the measures was significantly ( P  < 0.05) 
different from results obtained previously from 18 
patients with a clinical diagnosis of CIDP who were 
not treated with plasma exchange. Responding pa- 
tients did demonstrate significantly reduced con- 
duction, as measured by F-response latency and 
terminal conduction velocity, when compared with 
nonresponding patients. Conduction velocity (as 
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Table 4. Electrodlagnostic results 
Responders Nonresponders 
mean + SEM mean ? SEM 
Conduction studies$ (n  = 7) ( n  = 4) 
Motor 
Amplitude (1) 
Conduction velocity (1) 
Terminal conduction (1) 
F-response latency (2) 
Temporal dispersion (3) 
Amplitude (1) 
Conduction velocity (1) 
Terminal latency (1) 
Needle electromyography 






MUAP recruitment (5) 
35 + 12 
4 5 ?  7 
4 5 +  5 
210 * 22 
51 + 5 
13 & 6 
45 -t 15 
6 5 - t  8 
1.1 t 0.4 
2.1 5 0.5 
2.2 5 0.2 
1 4  5 0.4 
23 * 10 
63 + 10 
70 2 3 t  
119 + 4 t  
5 3 2  7 
21 + 9 
80 2 4' 
77 -c 9 
1.7 + 0.7 
1.8 2 0.5 
1.4 -e 0.7 
1.7 + 0.6 
*P < 0 05 
j P  < 0 07 
$Numbers in parenfheses I = percent of normal mean, 2 = percent of 
upper limit of normal, 3 = ratio of prox/ma/ld/sta/ amp/ft,dde x 100, 
4 = 0 (normal) to 4 + (profuse). 5 = 0 (none) to 4 + (normal) 
measured in the forearm and leg, respectively) was 
correspondingly reduced in responding patients, 
but did not reach statistical significance. 
Serial pre- and post-plasma exchange electro- 
diagnostic studies were performed on all but 
one patient (patient 9). Of the seven patients clini- 
cally responding to plasma exchange, six demon- 
strated improved conduction study results for mul- 
tiple nerve assessment in at least two (average 5.3) 
of the following parameters: evoked amplitude, 
terminal conduction, conduction velocity, and F- 
response latency. The sole patient (patient 4) with 
deterioration in electrodiagnostic results despite 
clinical improvement following plasma exchange 
nevertheless showed an impressive clinical change 
(FSI improvement of 6 grades). 'The most coninion 
parameters reflecting improvement were motor 
and sensory evoked amplitudes and terminal con- 
duction. 
DISCUSSION 
CIDP has been treated with several therapeutic 
agents since its original description.2.3 Prineas and 
McLeod2' described improvement in 13 of 17 pa- 
tients with relapsing CIDY treated with prednisone 
or ACTH. In the largest series to date of patients 
with CIDP, Dyck et aL7 reported improvement fol- 
lowing corticosteroid use in 39% of patients. Using 
objective clinical and electrodiagnostic monitoring, 
they demonstrated a small, but significant im- 
provement over no treatment in a 3-month trial of 
prednisone in 28 patients with CIDP.' Other re- 
ports have documented similar results in smaller 
trials."."."3 
Several case reports and small series describe 
reversal of symptoms and signs in CIDP with 
azathioprine,lq& I W f i  In several instances, azathio- 
pririe produced improvement in patients who were 
previously unresponsive to steroids or allowed re- 
placement of steroids with azathioprine.ii.ln Less 
commonly prescribed, but occasionally effective, 
medications include cyclophospharnide,"."" nitro- 
gen mustard"' and poly-ICI,C.' 
Several case reports describe improvement in 
In- 
cluded are patients treated with plasma exchange 
only, or patients treated in combination with corti- 
costeroids or cyclophospharnide. I n  the report of 
Levy et al.,16 the clinical disease course had been 
refractory to previous corticosteroid administra- 
tion. Only one of three CIDP patients reported by 
Dalakas and Engel' improved following plasnia ex- 
change, and this improvement was characterized 
as minimal. In addition, only one of two patients 
described by Gross et al." improved subsequent to 
plasma exchange. In the largest series to date of 
plasma exchange in CIDP, marked clinical im- 
provement (two patients) and partial improvement 
(three patients) occurred in five o f  seven patients 
undergoing plasma exchange.25 The use of supple- 
mental corticosteroids or other immunosuppr-es- 
sants was not described. 
Plasma exchange is of unproven berielit in 
CIDP. Nonetheless, our experience with 11 un- 
selected, consecutive patients suggests that plasma 
exchange may result in rapid improvement, even 
in patients with a chronic progressive history who 
were previously unresponsive or intolerant to cor- 
ticosteroids. None of our patients had been previ- 
ously treated or had plasma exchange supple- 
mented with other irnmunosuppressants. 
A surprising result from this study was the ob- 
servation that plasma exchange may result in con- 
tinued improvement beyond the first weeks follow- 
ing exchange. All seven patients responding to 
plasma exchange showed progressive improve- 
ment beyond the first month subsequent to ex- 
change, and several continued to gain strength 
beyond the 6-month follow-up. This improvement 
evolved in the setting of a tapering of the dose of 
corticosteroids. Because the mechanism of the 
benefit of plasma exchange is still unknown in cie- 
niyelinating neuropathies, a satisfactory explana- 
CIDP following plasma exchange.' ' ~ " i , " ~ 2 '  
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tion for the prolonged effect of plasma exchange 
eludes us. Possibly, repair and remyelination of pe- 
ripheral nerve transpires slowly over months, or 
"antibody" removal by plasma exchange is not its 
sole mechanism of action. 
Also unexplained are the electrodiagnostic 
findings that patients responding to plasma ex- 
change statistically had longer F-response latencies 
and slower motor terminal conduction. This result 
suggests a fascinating hypothesis that plasma ex- 
change may be most beneficial in reversing exten- 
sive proximal and distal demyelination. Whether 
or  not potential responders to plasma exchange in 
CIDP might be predicted on the basis of nerve 
conduction results awaits more controlled studies 
on larger patient populations. 
At present, removal of a presumed antibody 
directed against peripheral nerve myelin is the 
most intuitively satisfying explanation for im- 
provement following plasma exchange in CIDP. 
Pathologic studies in CIDP have revealed features 
similar to those observed in AIDP and in animals 
with experimental allergic neuritis (EAN), namely, 
scattered areas of circumscribed myelin lost in the 
presence of lymphocytes and macrophages, promi- 
nent onion bulb formation, and axonal loss."' 
These findings strongly suggest an immunologic 
process, but it is unclear whether o r  not that pro- 
cess is primarily humoral, cell-mediated, o r  a com- 
bination of both. 
Dalakas and Engel," on examining frozen sec- 
tions of sural nerve biopsies of nine patients with 
CIDP, found linear depositions of IgM in six pa- 
tients and IgG in three patients on what appeared 
to be the exterior portion of the Schwann cell plas- 
malemma. They postulated that the major antigen 
in CIDP may be a superficial plasmalemmal car- 
bohydrate group that elicits a persistent IgM re- 
sponse, with subsequent immunoglobulin binding 
to the Schwann cell surface. Demyelination in rat 
sciatic nerve has been demonstrated following pas- 
sive transfer of fresh serum from patients with 
AIDP, yet whether or  not serum from patients 
with CIDP also produces demylination when in- 
jected into nerve is Thus far, anti- 
myelin antibodies have not been reported in CIDP, 
and Leibowitz and HughesI5 could not demon- 
strate antibodies to P2 by radioimmunoassay or to 
galactocerebroside by a complement-fixing tech- 
nique. Whether or not an antibody is the initiator 
of myelin damage in CIDP o r  AIDP is uncertain. 
Yonezawa et al.," in an EAN model, detected a 
serum factor which caused macrophages to adhere 
to and demyelinate normal myelin sheaths in 
vitro. 
Cell-mediated immunity studies in patients 
with CIDP have also demonstrated a heightened 
response. Sheremata et al." reported enhanced 
macrophage migration inhibition factor release to 
a homogenate of human sciatic nerve in the lym- 
phocytes of one patient with CIDP. In addition, 
lymphocyte transformation was magnified on ex- 
posure to CNS MBP and a peripheral nerve MBP 
(myelin basic protein) in four patients with CIDP.' 
Clarification of the efficacy of plasma exchange 
in progressive CIDP awaits further prospective 
randomized trials. T h e  identification of apparent 
electrodiagnostic differences between responding 
and nonresponding patients in this unselected con- 
secutive patient trial suggests that these measures 
must be controlled o r  closely evaluated in future 
randomized studies. 
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